Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK cells + monoclonal antibodies (Zhejiang University)
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This therapeutic approach involves the infusion of natural killer (NK) cells in combination with monoclonal antibodies for the treatment of hematological malignancies, specifically relapsed or refractory acute myeloid leukemia (AML). NK cells are innate immune effector cells capable of direct tumor lysis. The addition of monoclonal antibodies is intended to enhance the anti-tumor response through antibody-dependent cellular cytotoxicity (ADCC). In this mechanism, the antibodies bind to tumor-associated antigens, and the NK cells recognize the Fc portion of these antibodies via their CD16 (FcγRIIIa) receptors, leading to targeted cell death. This specific protocol is being evaluated in clinical trials sponsored by Zhejiang University to improve outcomes in patients who have failed standard therapies.
- Other names
- NK cells/Combined Monoclonal AntibodiesNK cells and monoclonal antibodies in R/R AML
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)LAB (Labyrinthin)
Beyond the preview
Go deeper on NK cells + monoclonal antibodies (Zhejiang University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK cells + monoclonal antibodies (Zhejiang University).